RxDoctor Payments Data

Steven Jacobs, MD

Internal Medicine · Beverly Hills, CANPI 1750455259

Payments from drug & device makers

$6,286in general payments, 2019–2025

Across 277 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$609
  • GSK$598
  • Boehringer Ingelheim$512
  • Pfizer$382
  • Bausch Health US, LLC$263
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$6,286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,286 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$192,491
Medicare patients
306
Services billed
3,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab43$33,751
OzempicSemaglutide38$33,045
JardianceEmpagliflozin35$28,969
EliquisApixaban31$28,489
VimpatLacosamide11$26,447
JanuviaSitagliptin Phosphate26$18,610
MounjaroTirzepatide17$18,028
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,134
Testosterone40$6,339
SynthroidLevothyroxine Sodium84$5,986
Ezetimibe128$3,028
Atorvastatin Calcium317$2,915
Rosuvastatin Calcium208$2,505
Fentanyl12$2,424
Zolpidem Tartrate79$2,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$123$33,04538 claims
Boehringer IngelheimJardiance$512$28,96935 claims
PfizerEliquis$382$28,48931 claims
MerckJanuvia$52$18,61026 claims
Lilly USA, LLCMounjaro$216$18,02817 claims
GSKTrelegy Ellipta$598$10,13414 claims
AbbVieSynthroid, Armour Thyroid$609$6,470106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →